. Author manuscript; available in PMC: 2021 Feb 22.

Published in final edited form as: Clin Gastroenterol Hepatol. 2020 Feb 13;18(13):2952–2961.e8. doi: 10.1016/j.cgh.2020.02.010

Table 3.

Diagnostic Performance of Clinical Decision Support Tool in the VICTORY Cohort Among Vedolizumab-Treated Patients

	Sensitivity (95% Cl) (%)	Specificity (95% Cl) (%)	Positive likelihood ratio (95% Cl)	Negative likelihood ratio (95% Cl)
26 points
Corticosteroid-free remission^a at 26 wk	93 (79–98)	15 (10–21)	1.08 (0.97–1.21)	0.50 (0.16–1.61)
Colectomy-free at 26 wk	88 (83–92)	29 (8–58)	1.23 (0.88–1.73)	0.42 (0.17–1.04)
32 points
Corticosteroid-free remission^a at 26 wk	51 (35–67)	68 (60–75)	1.59 (1.09–2.31)	0.72 (0.52–1.00)
Colectomy-free at 26 wk	37 (30–44)	71 (42–92)	1.29 (0.55–3.01)	0.89 (0.62–1.26)

CI, confidence interval; VICTORY, Vedolizumab for Health Outcomes in Inflammatory Bowel Diseases.

Remission defined as full Mayo score of ≤2 points with no subscore >1 point and being off steroids.